Samsung Bioepis partner brings biosimilars to China
Samsung Bioepis will expand into the Chinese market after agreeing to a deal with 3SBio to commercialise its biosimilar portfolio.
Archives for January 16, 2019
PCI invests $20m in biologic manufacturing capabilities
PCI Pharma utilizes $20m for the expansion of its center for excellence and cold chain capabilities to meet the growth of the biologics market.